A phase III trial of chidamide (HBI-8000; Tucidinostat) in patients with hormone receptor-positive, HER-2 negative late stage breast cancer
Phase of Trial: Phase III
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Tucidinostat (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GNT Biotech and Medicals Corporation
- 21 Jun 2018 According to a GNT Biotech and Medicals Corporations media release, status changed from not yet recruiting to recruiting.
- 20 Apr 2017 New trial record
- 19 Apr 2017 According to a company media release, GNTbm will be using the same clinical trial protocol (see CT profile 258143) as used by Chipscreen Biosciences for this trial.